Overall rank by patents
#29,728
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 8 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
The verdict
Piramal holds 9 US patents across 8 technology areas, rank #29,728 of 50,000 tracked assignees.
Piramal Pharma Limited has been granted 9 US utility patents between 2021 and 2025, placing Piramal Pharma Limited at rank #29,728 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 7.3 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, Piramal Pharma Limited is one of the more focused assignees in the PatentsView dataset. By volume, Piramal sits between Pharmain Corporation (9 patents, rank #29,724) and Playfusion Limited (9 patents, rank #29,732) - the closest US assignees by grant volume. The composite Innovation Score of 42.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Piramal Pharma Limited's 7.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Piramal Pharma Limited against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PHARMAIN CORPORATION
9 patents
PI INDUSTRIES LTD.
9 patents
PINNACLE SEED, INC.
9 patents
PIPL LIMITED
9 patents
PITT-OHIO Express, LLC
9 patents
PLANET LABS PBC
9 patents
PLANTARC BIO LTD.
9 patents
PLAYFUSION LIMITED
9 patents
PIRAMAL PHARMA LIMITED
9 patents
What this shows Piramal holds 9 patents at rank #29,728, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,728 in granted patent volume.
Other assignees with the most granted patents in Piramal's primary technology class.
Piramal's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
42 Top 31% higher than 69% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 11.1% |
| 2022 | 6 | 66.7% |
| 2025 | 2 | 22.2% |
Top 8 of 8 technology areas
Overall rank by patents
#29,728
Across all tracked assignees
42.4 out of 100
How to use this portfolio
Piramal's 9 grants land it in the top 31% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.